Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Author(s): Divyanshi Gupta, Pranay Wal, Mudita Mishra, Ankita Wal*, Shruti Rathore, Shiv Shanker Pandey, Nikita Saraswat and Bhagawati Saxena

DOI: 10.2174/0127724328237059230919093818

DownloadDownload PDF Flyer Cite As
Recent Progress in the Understanding and Management of Acute Mountain Sickness: A Narrative Review

Page: [213 - 224] Pages: 12

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Background: Individuals at higher altitudes may experience a decrease in blood oxygen levels, which can result in a variety of clinical illnesses, such as high-altitude pulmonary edema, high-altitude cerebral edema, and milder but more common acute mountain sickness (AMS).

Objective: This study aims to review the current state of knowledge related to motion sickness, the risk of AMS, and pharmacological and non-pharmacological treatments for AMS.

Methods: Several databases, including PubMed, Bentham Science, Elsevier, Springer, and Research Gate, were used to compile the data for the article following a thorough analysis of the various research findings connected to acute mountain sickness and motion sickness, along with treatments and prevention.

Results: This article covers the research on mountain sickness as well as every imaginable form of conventional and alternative medicine. It contains ten medicinal plants that are useful in treating mountain sickness and various other remedies. Additionally, case studies are provided.

Conclusion: Therefore, the information in the paper will help travel medicine specialists better personalize their appropriate care for patients who travel to high-altitude locations. Additionally, all available antiemetic medications, serotonin agonists, nonsteroidal anti-inflammatory drugs, and herbal treatments for motion sickness were discussed. The prevention and consequences of acute mountain sickness are also covered in this study.

Keywords: Acute mountain sickness, nausea, motion sickness, treatment for motion sickness, prevention for motion sickness, complications of mountain sickness.

Graphical Abstract

[1]
Tapia L, Irarrázaval S. Acetazolamide for the treatment of acute mountain sickness. Medwave 2019; 19(11): e7736.
[http://dx.doi.org/10.5867/medwave.2019.11.7736] [PMID: 31891352]
[2]
Obrowski M. Deadly high altitude pulmonary disorders: Acute mountain sickness (ams); high altitude pulmonary edema (HAPE) and high-altitude cerebral edema (HACE): A clinical review. IJOPRS 2016; 1(1): 6-12.
[3]
Hackett PH, Roach RC. High altitude cerebral edema. High Alt Med Biol 2004; 5(2): 136-46.
[http://dx.doi.org/10.1089/1527029041352054] [PMID: 15265335]
[4]
Iqbal A, Majoo S. A case report of high altitude sickness with features of acute mountain sickness (AMS), high altitude cerebral edema (HACE) and high altitude pulmonary edema (HAPE). IJCA 2016; 3(1): 131.
[http://dx.doi.org/10.5958/2394-4994.2016.00020.2]
[5]
Motion Sickness. PedPat Educ 2021.
[6]
Hackett PH. The cerebral etiology of high-altitude cerebral edema and acute mountain sickness. Wilderness Environ Med 1999; 10(2): 97-109.
[http://dx.doi.org/10.1580/1080-6032(1999)010[0097:TCEOHA]2.3.CO;2] [PMID: 10442158]
[7]
Stripe E. High altitude pulmonary edema at moderate altitude: Report of two cases and review of literature. JLPRR 2021; 6(1) .
[8]
Raut M, Maheshwari A. Low oxygen saturation: Really a hypoxia? Saudi J Anaesth 2015; 9(2): 229-30.
[http://dx.doi.org/10.4103/1658-354X.152901] [PMID: 25829925]
[9]
Perry SF. HYPOXIA | Respiratory responses to hypoxia in fishes. In: Encyclopedia of Fish Physiology From Genome to Environment. 2011; pp. 1751-6.
[10]
LaManna JC. Hypoxia in the central nervous system. Essays Biochem 2007; 43: 139-51.
[11]
Lacerte M, Mesfin FB. Hypoxic Brain Injury. StatPearls 2020.
[12]
Motion Sickness Glossary. Words, phrases, terms and meanings Available from: www.motion-sickness-guru.com
[13]
Golding J, Gresty M, Bronstein A. Vertigo and dizziness from environmental motion: Visual vertigo, motion sickness, and drivers’ disorientation. Semin Neurol 2013; 33(3): 219-30.
[http://dx.doi.org/10.1055/s-0033-1354602] [PMID: 24057825]
[14]
Cheung B, Nakashima AM, Hofer KD. Various anti-motion sickness drugs and core body temperature changes. Aviat Space Environ Med 2011; 82(4): 409-15.
[http://dx.doi.org/10.3357/ASEM.2903.2011] [PMID: 21485398]
[15]
Murdoch DR, Pollard AJ. Acute Mountain Sickness. J Travel Med 1997; 4(2): 90-3.
[http://dx.doi.org/10.1111/j.1708-8305.1997.tb00786.x] [PMID: 9815488]
[16]
Motion Sickness. 2016. Available from: https://my.clevelandclinic.org/health/articles/12782-motion-sickness
[17]
Wang K, Zhang M, Li Y, et al. Physiological, hematological and biochemical factors associated with high-altitude headache in young Chinese males following acute exposure at 3700 m. J Headache Pain 2018; 19(1): 59.
[http://dx.doi.org/10.1186/s10194-018-0878-7] [PMID: 30046908]
[18]
Bärtsch P, Saltin B. General introduction to altitude adaptation and mountain sickness. Scand J Med Sci Sports 2008; 18(S1): 1-10.
[http://dx.doi.org/10.1111/j.1600-0838.2008.00827.x] [PMID: 18665947]
[19]
Karaytuğ K, Ekinci M, Yücekul A. Unnoticed etiology in orthopedic complaints: Chronic mountain sickness. J Ist Faculty Med 2022; 85(1): 98-104.
[http://dx.doi.org/10.26650/IUITFD.929597]
[20]
Scurr JH, Gulati OP. Zinopin® - the rationale for its use as a food supplement in traveller’s thrombosis and motion sickness. Phytother Res 2004; 18(9): 687-95.
[http://dx.doi.org/10.1002/ptr.1575] [PMID: 15478211]
[21]
Mountain Sickness. Available from: https://illness.com/disease/ mountain-sickness/#:~:text=In%20most%20cases%2C%20symptoms%20are%20mild.%20Symptoms%20of
[22]
Geez T. What is mountain sickness and why does it happen? 2020. Available from: https://oldgeezerhiking.com/mountain-sickness/
[23]
Wille M, Gatterer H, Mairer K, et al. Short-term intermittent hypoxia reduces the severity of acute mountain sickness. Scand J Med Sci Sports 2012; 22(5): e79-85.
[http://dx.doi.org/10.1111/j.1600-0838.2012.01499.x] [PMID: 22853822]
[24]
Chong CMY. High altitude pulmonary edema with pulmonary embolism in high altitude traveller – a case report. CREM 2022; 2(3): 1-2.
[http://dx.doi.org/10.54026/CREM/1025]
[25]
Zubieta-Calleja G, Zubieta-DeUrioste N. RETRACTED: Acute mountain sickness, high altitude pulmonary edema, and high altitude cerebral edema: A view from the High Andes. Respir Physiol Neurobiol 2021; 287: 103628.
[http://dx.doi.org/10.1016/j.resp.2021.103628] [PMID: 33545376]
[26]
Bärtsch P. High-altitude pulmonary oedema: Pathophysiology and treatment. Eur J Anaesthesiol 2000; 17(20): 12.
[http://dx.doi.org/10.1097/00003643-200000003-00023]
[27]
Maggiorini M. High altitude-induced pulmonary oedema. Cardiovasc Res 2006; 72(1): 41-50.
[http://dx.doi.org/10.1016/j.cardiores.2006.07.004] [PMID: 16904089]
[28]
Dehnert C, Grünig E, Mereles D, von Lennep N, Bärtsch P. Identification of individuals susceptible to high-altitude pulmonary oedema at low altitude. Eur Respir J 2005; 25(3): 545-51.
[http://dx.doi.org/10.1183/09031936.05.00070404] [PMID: 15738301]
[29]
Fisher O, Benson RA, Wayte S, Kimani PK, Hutchinson C, Imray CHE. Multimodal analysis of the effects of dexamethasone on high-altitude cerebral oedema: protocol for a pilot study. Trials 2019; 20(1): 604.
[http://dx.doi.org/10.1186/s13063-019-3681-0] [PMID: 31651350]
[30]
Abouzari M, Cheung D, Pham T, et al. The relationship between vestibular migraine and motion sickness susceptibility. Otol Neurotol 2020; 41(8): 1116-21.
[http://dx.doi.org/10.1097/MAO.0000000000002705] [PMID: 32501936]
[31]
Alizadeh R, Ziaee V, Aghsaeifard Z, Mehrabi F, Ahmadinejad T. Characteristics of headache at altitude among trekkers; A comparison between acute mountain sickness and non-acute mountain sickness headache. Asian J Sports Med 2012; 3(2): 126-30.
[http://dx.doi.org/10.5812/asjsm.34714] [PMID: 22942999]
[32]
Kapoor R, Narula AS, Anand AC. Treatment of acute mountain sickness and high altitude pulmonary oedema. Med J Armed Forces India 2004; 60(4): 384-7.
[http://dx.doi.org/10.1016/S0377-1237(04)80018-2] [PMID: 27407680]
[33]
Levine BD, Yoshimura K, Kobayashi T, Fukushima M, Shibamoto T, Ueda G. Dexamethasone in the treatment of acute mountain sickness. N Engl J Med 1989; 321(25): 1707-13.
[http://dx.doi.org/10.1056/NEJM198912213212504] [PMID: 2687688]
[34]
Kamimori GH, Ryan EJ, Otterstetter R, Barkley JE, Glickman EL, Davis HQ. Catecholamine levels in hypoxia-lnduced acute mountain sickness. Aviat Space Environ Med 2009; 80(4): 376-80.
[http://dx.doi.org/10.3357/ASEM.2336.2009] [PMID: 19378908]
[35]
Mellor AJ, Woods DR, O’Hara J, Howley M, Watchorn J, Boos C. Rating of perceived exertion and acute mountain sickness during a high-altitude trek. Aviat Space Environ Med 2014; 85(12): 1214-6.
[http://dx.doi.org/10.3357/ASEM.4083.2014] [PMID: 25479264]
[36]
Imray C, Wright A, Subudhi A, Roach R. Acute mountain sickness: Pathophysiology, prevention, and treatment. Prog Cardiovasc Dis 2010; 52(6): 467-84.
[http://dx.doi.org/10.1016/j.pcad.2010.02.003] [PMID: 20417340]
[37]
Thomas B, Valappila P, Rouf A. Medication used in nausea and vomiting of pregnancy - a review of safety and efficacy. Ob/Gyn 2015; 05(270): 2161-932.
[38]
National Institute on Drug Abuse. 2019. Available from: https://nida.nih.gov/publications/drugfacts/treatment-approaches-drug-addiction
[39]
Villafuerte FC, Corante N. Chronic mountain sickness: Clinical aspects, etiology, management, and treatment. High Alt Med Biol 2016; 17(2): 61-9.
[http://dx.doi.org/10.1089/ham.2016.0031] [PMID: 27218284]
[40]
MacDiarmid S. Better management of patients with overactive bladder with antimuscarinics? Int J Clin Pract 2008; 62(1): 3-4.
[http://dx.doi.org/10.1111/j.1742-1241.2007.01627.x] [PMID: 18173809]
[41]
Kanbayashi Y, Hosokawa T. Predictive factors for nausea or vomiting in patients with cancer who receive oral oxycodone for the first time: Is prophylactic medication for prevention of opioid-induced nausea or vomiting necessary? J Palliat Med 2014; 17(6): 683-7.
[http://dx.doi.org/10.1089/jpm.2013.0613] [PMID: 24702605]
[42]
Spinks A, Wasiak J. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Libr 2011; 2011(6): CD002851.
[http://dx.doi.org/10.1002/14651858.CD002851.pub4] [PMID: 21678338]
[43]
Burton MJ, Roland PS, Rosenfeld RM. Extracts from The Cochrane Library: Scopolamine (hyoscine) for preventing and treating motion sickness. Otolaryngol Head Neck Surg 2010; 142(4): 468-71.
[http://dx.doi.org/10.1016/j.otohns.2010.01.036] [PMID: 20304263]
[44]
Mohaghegh Z, Abedi P, Faal S, et al. The effect of hyoscine n- butylbromide on labor progress: A systematic review. BMC Preg and Childbirth 2020; 20(1): 291.
[45]
Medications to Prevent and Treat Motion Sickness. 2015. Available from: https://www.travelbughealth.com/bugs-blog/ medications-toprevent-and-treat-motion-sickness
[46]
Karrim N, Magula N, Saman Y. Antihistamines for motion sickness. Cochrane Libr 2017.
[http://dx.doi.org/10.1002/14651858.CD012715] [PMID: 36250781]
[47]
Yang TD, Pei JS, Yang SL, Liu ZQ, Sun RL. Medical prevention of space motion sickness—animal model of therapeutic effect of a new medicine on motion sickness. Adv Space Res 2002; 30(4): 751-5.
[http://dx.doi.org/10.1016/S0273-1177(02)00391-5] [PMID: 12528715]
[48]
Shapiro R. Ondansetron for the treatment of nausea associated with altitude sickness. Wilderness Environ Med 2008; 19(4): 317-8.
[http://dx.doi.org/10.1580/07-WEME-LE-176.1] [PMID: 19099324]
[49]
Vansola R, Gohil S, T Kulkarni A. Comparison of ondansetron with dexamethasone and ondansetron in prevention of postoperative nausea vomiting in laparoscopic abdominal surgery. Indian J Appl Res 2021; 6-7.
[http://dx.doi.org/10.36106/ijar/0700258]
[50]
Murdin L, Golding J, Bronstein A. Managing motion sickness. BMJ 2011; 343(1): d7430.
[http://dx.doi.org/10.1136/bmj.d7430] [PMID: 22138695]
[51]
Dellwo A. Double-blind, placebo-controlled clinical trial basics 2008. Available from: https://www.verywellhealth.com/double-blind-placebo-controlled-clinical-trial-715861
[52]
Albert EG. Phenytoin for the prevention of motion sickness. Med J Aust 2003; 178(11): 575-6.
[http://dx.doi.org/10.5694/j.1326-5377.2003.tb05362.x] [PMID: 12765507]
[53]
Fleischhackl R, Dörner C, Scheck T, et al. Reduction of motion sickness in prehospital trauma care. Anaesthesia 2003; 58(4): 374-8.
[http://dx.doi.org/10.1046/j.1365-2044.2003.03082_4.x] [PMID: 12688274]
[54]
Panoff L. Is Ginger a Safe and Effective Treatment for Nausea? 2019. Available from: https://www.healthline.com/nutrition/ginger-for-nausea
[55]
Fiore DC, Hall S, Shoja P. Altitude illness: Risk factors, prevention, presentation, and treatment. Am Fam Physician 2010; 82(9): 1103-10.
[PMID: 21121556]
[56]
Hackett P, Shlim D. High Elevation Travel & Altitude Illness Available from: https://wwwnc.cdc.gov/travel/yellowbook/2020/noninfectious-health-risks/high-altitude-travel-and-altitude-illness
[57]
Treatment of chronic mountain sickness. Case Rep Med 2020.
[58]
Acetazolamide is an effective treatment for chronic mountain sickness. Inpharma Weekly 2006; 1526: 14.
[59]
Mountain Sickness In: Pediatric Patient Education. 2021.
[60]
Singh S, Kumar N, Verma R, Nehra A, Kumar S. The Effects of high frequency repetitive transcranial magnetic stimulation on negative symptoms of schizophrenia: Findings from a randomized, double-blind, sham-controlled trial. Brain Stimul 2019; 12(2): 479.
[http://dx.doi.org/10.1016/j.brs.2018.12.564]
[61]
Dunham-Snary KJ, Wu D, Sykes EA, et al. Hypoxic pulmonary vasoconstriction. Chest 2017; 151(1): 181-92.
[http://dx.doi.org/10.1016/j.chest.2016.09.001] [PMID: 27645688]
[62]
Ilaiyaraja N, Singsit D, Patil MM, Priyadharshini S, Rashmi V, Khanum F. Motion sickness-relieving effects of Tamzin, a herbal formulation: In vitro and in vivo studies. Food Biosci 2020; 35: 100595.
[http://dx.doi.org/10.1016/j.fbio.2020.100595]
[63]
Zhang W, Cao Y, Chen S, Li F, Chen X, Liu Y. Integrated metabolomics and network pharmacology approach to exploring the potential mechanism of tianxiang capsule for treating motion sickness. J Ethnopharmacol 2021; 275: 114107.
[http://dx.doi.org/10.1016/j.jep.2021.114107] [PMID: 33845144]
[64]
Maheswari DU, Anand T, Padma A, Ilaiyaraja N, Khanum F. Evaluation of the effect of herbal extracts and their bioactive compounds against motion sickness by regulating neurotransmitter levels in vitro and in vivo. S Afr J Bot 2020; 130: 130-40.
[http://dx.doi.org/10.1016/j.sajb.2019.12.012]
[65]
Gabry AL, Ledoux X, Mozziconacci M, Martin C. High-altitude pulmonary edema at moderate altitude (< 2,400 m; 7,870 feet): A series of 52 patients. Chest 2003; 123(1): 49-53.
[http://dx.doi.org/10.1378/chest.123.1.49] [PMID: 12527602]
[66]
Viola P, Gioacchini FM, Astorina A, et al. The pharmacological treatment of acute vestibular syndrome. Front Neurol 2022; 13: 999112.
[http://dx.doi.org/10.3389/fneur.2022.999112] [PMID: 36158968]
[67]
Mazur K, Machaj D, Jastrzębska S, Płaczek A, Mazur D. Significance of the proper acclimatization, use of the acetazolamide and dexamethasone in prevention of acute mountain sickness (AMS) – literature review. J Educ 2020; 10(2): 66-73.
[68]
Pilmanis AA, Webb JT, Balldin UI, Conkin J, Fischer JR. Air break during preoxygenation and risk of altitude decompression sickness. Aviat Space Environ Med 2010; 81(10): 944-50.
[http://dx.doi.org/10.3357/ASEM.2819.2010] [PMID: 20922886]
[69]
Toda K. Are topical non-steroidal anti-inflammatory drugs (NSAIDs) safer than oral NSAIDs? Or are the adverse effects of topical NSAIDs comparable to those of oral NSAIDs? Osteoarthritis Cartilage 2021; 29(11): 1624-5.
[http://dx.doi.org/10.1016/j.joca.2021.08.010] [PMID: 34506943]
[70]
Pandit A, Karmacharya P, Pathak R, Giri S, Aryal MR. Efficacy of NSAIDs for the prevention of acute mountain sickness: a systematic review and meta-analysis. J Community Hosp Intern Med Perspect 2014; 4(4): 24927.
[http://dx.doi.org/10.3402/jchimp.v4.24927] [PMID: 25317267]
[71]
Mee MJ, Egerton-Warburton D, Meek R. Treatment and assessment of emergency department nausea and vomiting in Australasia: A survey of anti-emetic management. Emerg Med Australas 2011; 23(2): 162-8.
[http://dx.doi.org/10.1111/j.1742-6723.2011.01386.x] [PMID: 21489163]
[72]
van Patot MCT, Keyes LE, Leadbetter G III, Hackett PH. Ginkgo biloba for prevention of acute mountain sickness: Does it work? High Alt Med Biol 2009; 10(1): 33-43.
[http://dx.doi.org/10.1089/ham.2008.1085] [PMID: 19278351]
[73]
Caspersen C, Stensrud T, Thorsen E. Bronchial nitric oxide flux and alveolar nitric oxide concentration after exposure to hyperoxia. Aviat Space Environ Med 2011; 82(10): 946-50.
[http://dx.doi.org/10.3357/ASEM.2995.2011] [PMID: 21961398]
[74]
Nespoulet H. Alternative Treatments in Acute Mountain Sickness (TAIA). Patent NCT03956472, 2019.
[75]
Manolea A. Meditation as adaptation strategy. Procedia Soc Behav Sci 2014; 127: 631-5.
[http://dx.doi.org/10.1016/j.sbspro.2014.03.325]
[76]
Luo Y, Yang X, Gao Y. Strategies for the prevention of acute mountain sickness and treatment for large groups making a rapid ascent in China. Int J Cardiol 2013; 169(2): 97-100.
[http://dx.doi.org/10.1016/j.ijcard.2013.08.059] [PMID: 24095160]
[77]
Rossetti GMK, Macdonald JH, Wylie LJ, et al. Dietary nitrate supplementation increases acute mountain sickness severity and sense of effort during hypoxic exercise. J Appl Physiol 2017; 123(4): 983-92.
[http://dx.doi.org/10.1152/japplphysiol.00293.2017] [PMID: 28684588]
[78]
Hennis PJ, Mitchell K, Gilbert-Kawai E, et al. Effects of dietary nitrate supplementation on symptoms of acute mountain sickness and basic physiological responses in a group of male adolescents during ascent to Mount Everest Base Camp. Nitric Oxide 2016; 60: 24-31.
[79]
Gray D, Milne D. Effect of dietary supplements on acute mountain sickness. Percept Mot Skills 1986; 63(2): 873-4.
[http://dx.doi.org/10.2466/pms.1986.63.2.873] [PMID: 3808867]
[80]
Keshavarz B, Stelzmann D, Paillard A, Hecht H. Visually induced motion sickness can be alleviated by pleasant odors. Exp Brain Res 2015; 233(5): 1353-64.
[http://dx.doi.org/10.1007/s00221-015-4209-9] [PMID: 25633319]
[81]
Keshavarz B, Hecht H. Pleasant music as a countermeasure against visually induced motion sickness. Appl Ergon 2014; 45(3): 521-7.
[http://dx.doi.org/10.1016/j.apergo.2013.07.009] [PMID: 23957932]
[82]
Peck K, Russo F, Campos JL, Keshavarz B. Examining potential effects of arousal, valence, and likability of music on visually induced motion sickness. Exp Brain Res 2020; 238(10): 2347-58.
[http://dx.doi.org/10.1007/s00221-020-05871-2] [PMID: 32757060]
[83]
Sikri G, Singh K. Optic nerve sheath diameter and acute mountain sickness. J Ultrasound Med 2016; 35(2): 455-6.
[http://dx.doi.org/10.7863/ultra.15.08072] [PMID: 26795046]
[84]
Price D. Optic nerve sheath ultrasonography: A novel method for assessing intracranial pressure in acute mountain sickness. Acad Emerg Med 2006; 13(3): 354-5.
[http://dx.doi.org/10.1197/j.aem.2005.11.014]
[85]
Kanaan NC, Lipman GS, Constance BB, Holck PS, Preuss JF, Williams SR. Optic nerve sheath diameter increase on ascent to high altitude. J Ultrasound Med 2015; 34(9): 1677-82.
[http://dx.doi.org/10.7863/ultra.15.14.10060] [PMID: 26269295]
[86]
Herro E, Jacob SE. Mentha piperita (Peppermint). Dermatitis 2010; 21(6): 327-9.
[http://dx.doi.org/10.2310/6620.2011.10080] [PMID: 21144345]
[87]
Kumar S, Kumari R. Pharmacological activities of Ballota nigra (L.) benth: A mini review. Int J Pharma Bio Sci 2021; 10(3): 114-9.
[88]
Kamil M, Ahmad F, Abdallah MT. Phytochemical, pharmacognostic and pharmacological studies on Zingiber officinale. J Clin Lab Anal 2022; 5(1): 01-7.
[89]
Nandhini S, Narayanan KB, Ilango K. Valeriana officinalis: A review of its traditional uses, phytochemistry and pharmacology. Asian J Pharm Clin Res 2018; 11(1): 36.
[http://dx.doi.org/10.22159/ajpcr.2018.v11i1.22588]
[90]
D’ Andrea L. Variation of morphology, yield and essential oil components in common chamomile (Chamomilla recutita (L.) Rauschert) cultivars grown in Southern Italy. J Herbs Spices Med Plants 2002; 9(4): 359-65.
[http://dx.doi.org/10.1300/J044v09n04_14]
[91]
Musharaf K. Foeniculum vulgare Mill In: A Medicinal Herb. Medicinal Plant Research 2014.
[http://dx.doi.org/10.5376/mpr.2014.04.0006]
[92]
Acimovic M, Dojcinovic N. A review of pharmacological properties of anise (Pimpinella anisum L.). Lekovite sirovine 2014; 34(34): 3-17.
[http://dx.doi.org/10.5937/leksir1434003A]
[93]
Rivera-Ch M, León-Velarde F, Huicho L. Treatment of chronic mountain sickness: Critical reappraisal of an old problem. Respir Physiol Neurobiol 2007; 158(2-3): 251-65.
[http://dx.doi.org/10.1016/j.resp.2007.05.003] [PMID: 17580125]
[94]
Aikemu A, Zhang X, Hui SW, Maimaitiyiming D, Hu G. The treatment of Uygur medicine Dracocephalum moldavica L on chronic mountain sickness rat model. Pharmacogn Mag 2014; 10(40): 477-82.
[http://dx.doi.org/10.4103/0973-1296.141817] [PMID: 25422549]